News Archive

September 2021

CEVEC and UCB sign agreement for the use of CEVEC’s ELEVECTA® AAV manufacturing technology in Gene Therapy

CEVEC Pharmaceuticals GmbH (CEVEC) today announced the signing of an agreement with UCB S.A. (UCB; Euronext: UCB) on the evaluation and use of CEVEC’s proprietary ELEVECTA® Technology for the research, development, and manufacturing of Adeno-Associated Virus (AAV) vectors for gene therapy applications.

Read more …